Johnson & Johnson (J&J) subsidiary Cerenovus has announced €50m investment over the next three years at its site in Galway.
The project is being supported by taxpayers through state aid from IDA Ireland.
The company said c.30 specialist jobs will be created. The Ballybrit location currently has a workforce of 90 people.
Cerenovus Galway is a research site for stroke and is developing a portfolio of medical devices to treat this debilitating condition.
Ischemic stroke, caused by clots in vessels which block blood supply to the brain, accounts for 87% of all strokes, reportedly affecting one million patients every year in Europe.
In Association with
In Ireland, c.7,500 people have a stroke each year, and one-third of all strokes happen in people aged under 65.
Michael Gilvarry, GM at the Galway facility, commented: “We work closely with universities and academics, including strong collaborations locally with GMIT and NUI Galway.
“This investment will allow us to continue to conduct breakthrough research and push the boundaries of technology to put even better tools in the hands of physicians that make stroke treatment faster, easier, and even more effective.”
Cerenovus said the Galway facility features a world leading stroke simulation laboratory. The office space was expanded recently to include meeting and collaboration areas, as well as a space to facilitate team and physician collaborations with a focus on research, innovation, and product development.
Images: Getty & Supplied
